Vaccine safety experts from the World Health Organization (WHO) are meeting on Tuesday to review the Oxford-AstraZeneca jab after several European countries halted their rollouts.

There have been a number of cases in Europe of blood clots reported after the vaccine was administered.

But the numbers are below the level you would expect in the general population.

The UK medicines regulator and the WHO say there is no evidence of a link.

The European Medicines Agency (EMA) - the European Union's medicines regulator - is also meeting on Tuesday.

It is expected to issue its decision on the continued use of the Oxford-AstraZeneca vaccination on Thursday.

About 17 million people in the EU and the UK have received a dose of the vaccine, with fewer than 40 cases of blood clots reported as of last week, AstraZeneca said.

Concerns that there could be a link led to 11 European countries temporarily suspending use of the vaccine, including Germany, France, Italy and Spain.

Other countries, including Austria, have halted the use of certain batches of the drug as a precautionary measure.

However, Belgium, Poland, the Czech Republic and Ukraine said they would continue to administer the AstraZeneca vaccine.

And in Thailand, Prime Minister Prayuth Chan-ocha became the first person in the country to receive the AstraZeneca inoculation.

He and other members of the Thai cabinet had been due to receive their jabs on Friday, but regulators put the roll-out on hold following the suspensions in Europe.